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Cancer represents a public health problem worldwide with growing incidence as result of population aging, but also the
adoption of a cancer associated lifestyle.R1
The major problem of cancer is that most types are diagnosed on a later stage, reducing treatment effectiveness, so an early
diagnosis would considerably improve clinical outcome.R2 Cancer diagnosis, if based on molecular features, can be highly
specific and sensitive but very few biomarkers are available. Since most methodologies rely on known biomarkers to develop
molecular probes, discovery of unknown molecular features of diseased cells is very difficult.R3
SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is a procedure applied to perform an in vitro selection
from a random pool of nucleic acid sequences, called aptamers. These present specific binding to complex target mixtures,
due to their complex 3D structure, and high affinity to the ligand, comparable to monoclonal antibodies. 
Cell-SELEX allows using whole living cells as targets to select aptamers that specifically recognize them. Diseased cells usually
present specific biomarkers, such as wild-type proteins specifically or differentially expressed, with aberrant post translational
modifications, potentially resulting from genetic lesions. Aptamer probes selected against cancer cells are able to identify these
molecular differences, discriminating between normal and tumor cells, but also cells at different disease stages or from different
patients. Cell-SELEX has the advantage that aptamer selection can be done without prior knowledge of target molecules.R3
In this work, cancer cells and fibroblasts are being used to obtain a reduced pool of sequences that specifically recognize
cancer cells. After studying this pool, their binding affinity and detection will be tested and optimized. Generated aptamers
can be further combined with nanotechnology to obtain a multivalent nanovector for cancer diagnosis.
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